Insulet Corporation (PODD) - Total Liabilities
Based on the latest financial reports, Insulet Corporation (PODD) has total liabilities worth $1.68 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Insulet Corporation - Total Liabilities Trend (2002–2025)
This chart illustrates how Insulet Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore PODD long-term investments to assets to see how much of total assets are deployed in long-term investments.
Insulet Corporation Competitors by Total Liabilities
The table below lists competitors of Insulet Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Service Corporation International
NYSE:SCI
|
USA | $16.99 Billion |
|
American Airlines Group
NASDAQ:AAL
|
USA | $67.81 Billion |
|
Dundee Precious Metals Inc
TO:DPM
|
Canada | CA$497.04 Million |
|
Sanlam Ltd
JSE:SLM
|
South Africa | ZAC1.09 Trillion |
|
Airtac International Group
TW:1590
|
Taiwan | NT$11.35 Billion |
|
Harmony Gold Mining Company Limited
F:HAM
|
Germany | €62.42 Billion |
|
Groep Brussel Lambert NV
BR:GBLB
|
Belgium | €11.68 Billion |
|
Fresenius Medical Care AG & Co. KGaA
F:FMEA
|
Germany | €17.26 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down Insulet Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Insulet Corporation total assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Insulet Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Insulet Corporation (2002–2025)
The table below shows the annual total liabilities of Insulet Corporation from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.68 Billion | -10.71% |
| 2024-12-31 | $1.88 Billion | +1.11% |
| 2023-12-31 | $1.86 Billion | +4.55% |
| 2022-12-31 | $1.77 Billion | +18.91% |
| 2021-12-31 | $1.49 Billion | +17.58% |
| 2020-12-31 | $1.27 Billion | +18.96% |
| 2019-12-31 | $1.07 Billion | +48.89% |
| 2018-12-31 | $716.64 Million | +8.87% |
| 2017-12-31 | $658.23 Million | +67.28% |
| 2016-12-31 | $393.50 Million | +63.23% |
| 2015-12-31 | $241.07 Million | +10.42% |
| 2014-12-31 | $218.33 Million | +33.65% |
| 2013-12-31 | $163.36 Million | +6.16% |
| 2012-12-31 | $153.88 Million | +11.36% |
| 2011-12-31 | $138.19 Million | +53.54% |
| 2010-12-31 | $90.00 Million | -24.24% |
| 2009-12-31 | $118.79 Million | +13.18% |
| 2008-12-31 | $104.95 Million | +172.85% |
| 2007-12-31 | $38.47 Million | -75.79% |
| 2006-12-31 | $158.91 Million | +91.72% |
| 2005-12-31 | $82.88 Million | +15.71% |
| 2004-12-31 | $71.63 Million | +101.16% |
| 2003-12-31 | $35.61 Million | -1.54% |
| 2002-12-31 | $36.16 Million | -- |
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain… Read more